Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27556687 | 0.85 | LOXL2 (0.61) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL21914682 | 0.84 | LOXL2 (0.65) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL709955 | 0.84 | LOXL2 (0.59) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL28273108 | 0.83 | CA1 (0.56) | HPGDCA1CA2CA12CA9 | |
| SCHEMBL19584814 | 0.83 | CYP4A11 (0.58) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL1017999 | 0.82 | LOXL2 (0.58) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL22193540 | 0.82 | LOXL2 (0.62) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL6592668 | 0.81 | CA12 (0.51) | LOXL2CA1CA2CA12CA9 | |
| SCHEMBL12934512 | 0.80 | LOXL2 (0.37) | LOXL2CYP4A11HPGDCYP4F2CA1 | |
| SCHEMBL5969642 | 0.80 | LOXL2 (0.62) | LOXL2CYP4A11HPGDCYP4F2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-116987073-A | PI3K alpha/HDAC 6 subtype selective dual inhibitor and application thereof | 嘉兴学院 | 2023-11-03 | — | — | CN | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11518739-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| EP-1531812-A1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004010995-A1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003087066-A1 | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | SK CHEMICALS, CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
| WO-1994018165-A1 | SULFONAMIDE COMPOUNDS AS OPIOID K-RECEPTOR AGONISTS | PFIZER INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5210290-A | NMR diagnostic aid | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | disclosed |
| EP-0529292-A2 | Substituted aralkylsulfonyl-aminoguanidinoazines as herbizides | BAYER AG (DE) | 1993-03-03 | — | — | EP | disclosed |
| US-5130119-A | Sulfonamide or hydroxy fluorine substituted benzene for medical diagnosis | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | LOXL2 3209/4885CYP4A11 438/4885HPGD 3440/4885 |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | MAPK7, CNKSR1, MAPK1 | LOXL2 3477/4885CYP4A11 598/4885HPGD 992/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | LOXL2 1671/4885CYP4A11 921/4885HPGD 3140/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | LOXL2 839/4885CYP4A11 654/4885HPGD 678/4885 |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | LOXL2 2892/4885CYP4A11 4323/4885HPGD 62/4885 |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | LOXL2 839/4885CYP4A11 654/4885HPGD 678/4885 |
| US-11518739-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | LOXL2 3890/4885CYP4A11 309/4885HPGD 1578/4885 |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | LOXL2 1003/4885CYP4A11 276/4885HPGD 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.